A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Pancreatic Cancer
About this trial
This is an interventional treatment trial for Pancreatic Cancer
Eligibility Criteria
Inclusion Criteria:
- Metastatic pancreatic cancer with metastases amenable to biopsy
- Willingness to provide tissue and blood samples for research purposes
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
Exclusion Criteria:
- History of islet cell, acinar cell, or cystadenocarcinomas
- Prior cytotoxic chemotherapy for metastatic disease, except prior gemcitabine or FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin)
- Radiation therapy, immunotherapy or biologic therapy <28 days prior to study entry
Sites / Locations
- Mayo Clinic of Jacksonville
- Mayo Clinic
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
LY2090314 + Gemcitabine
LY2090314 + FOLFOX
LY2090314 + Gemcitabine + Nab-paclitaxel
LY2090314 given intravenously (IV) on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 milligram/square meter (mg/m^2) gemcitabine given IV on days 1, 8 and 15. Cohort closed to new enrollment per protocol addendum.
LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), and 15 in 28 day cycle in combination with FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle.
LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 mg/m^2 gemcitabine + 125 mg/m^2 nab-paclitaxel given IV on days 1, 8 and 15 in 28-day cycle. New cohort opened per protocol amendment.